US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.75 +0.06 (+0.39%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
News headline image
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? ↗
Via The Motley Fool
News headline image
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? ↗
12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts. 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗
Via The Motley Fool
News headline image
Why Summit Therapeutics Stock Is Jumping Today ↗
Via The Motley Fool
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Summit Therapeutics Rocketed 584% in 2024 ↗
Via The Motley Fool
News headline image
Where Will Summit Therapeutics Be in 5 Years? ↗
Via The Motley Fool
News headline image
How Is The Market Feeling About Summit Therapeutics? ↗
 
Via Benzinga
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst ↗
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
News headline image
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
News headline image
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Prediction: These 3 Healthcare Stocks Will Soar in 2025 ↗
Via The Motley Fool
News headline image
3 Stocks That Could Be Monster Winners in 2025 ↗
Via The Motley Fool
News headline image
3 Stocks That Could Turn $1,000 into $5,000 by 2030 ↗
Via The Motley Fool
News headline image
3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗
Via The Motley Fool
News headline image
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street ↗
Via The Motley Fool
News headline image
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today ↗
Via The Motley Fool
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday ↗
Via The Motley Fool
News headline image
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher ↗
Via The Motley Fool
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Via The Motley Fool
News headline image
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics Inc.
Via Business Wire
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics ↗
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
Via Investor's Business Daily
News headline image
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential ↗
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus. 
Via Benzinga
News headline image
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
News headline image
2 Hot Biopharma Stocks to Buy and Hold for 5 Years ↗
If you're patient, these businesses have a lot of promising projects in the works. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >